Galapagos N.V. Market Cap ($1.55 Billion)
Market Cap & Net Worth: Galapagos N.V. (GLPG)
Galapagos N.V. market cap. Galapagos N.V. (AS:GLPG) has a market capitalization of $1.55 Billion (€1.33 Billion) as of November 6, 2026. Listed on the AS stock exchange, this Netherlands-based company holds position #6872 globally and #48 in its home market, demonstrating a 13.22% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Galapagos N.V.'s stock price €26.90 by its total outstanding shares 65897071 (65.90 Million). Also see GLPG cash generation efficiency for how efficiently the company converts equity into cash flow.
Galapagos N.V. Market Cap History (2015–2026)
Galapagos N.V. market cap history from 2015 to 2026. Data shows change from $4.37 Billion to $2.07 Billion (-4.77% CAGR). Check Galapagos N.V. (GLPG) stock price for real-time trading data and today's change.
Index Memberships
Galapagos N.V. is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
AMX-Index
AMX
|
$86.91 Billion | 1.79% | #17 of 25 |
|
BEL-20 INDEX
BEL20
|
$378.41 Billion | 0.41% | #20 of 20 |
|
BEL-20 INDEX
BFX
|
$378.41 Billion | 0.41% | #20 of 20 |
|
BEL All Share
BSPT
|
$836.01 Billion | 0.19% | #39 of 108 |
Weight: Galapagos N.V.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Galapagos N.V. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Galapagos N.V.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Galapagos N.V. (GLPG) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.94x
Galapagos N.V.'s market cap is 1.94 times its annual revenue
Latest Price to Earnings (P/E) Ratio
6.72x
Galapagos N.V.'s market cap is 6.72 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $4.69 Billion | $129.52 Million | $54.01 Million | 36.25x | 86.92x |
| 2017 | $6.08 Billion | $127.09 Million | -$115.70 Million | 47.88x | N/A |
| 2018 | $6.21 Billion | $288.84 Million | -$29.26 Million | 21.49x | N/A |
| 2019 | $14.37 Billion | $844.99 Million | $149.84 Million | 17.00x | 95.89x |
| 2020 | $6.20 Billion | $478.05 Million | -$311.00 Million | 12.97x | N/A |
| 2021 | $3.79 Billion | $484.85 Million | -$125.42 Million | 7.82x | N/A |
| 2022 | $3.19 Billion | $505.28 Million | -$217.99 Million | 6.30x | N/A |
| 2023 | $2.85 Billion | $239.72 Million | $211.70 Million | 11.89x | 13.46x |
| 2024 | $2.04 Billion | $275.65 Million | $74.08 Million | 7.41x | 27.58x |
| 2025 | $2.16 Billion | $1.11 Billion | $320.88 Million | 1.94x | 6.72x |
Competitor Companies of GLPG by Market Capitalization
Companies near Galapagos N.V. in the global market cap rankings as of November 6, 2026. Also see Galapagos N.V. asset portfolio for a full breakdown of the balance sheet.
Key companies related to Galapagos N.V. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Galapagos N.V. (2015–2026)
Market capitalization of Galapagos N.V. from 2015 to today. Between 2015 and today, Galapagos N.V.'s market cap moved from $4.37 Billion to $ 2.07 Billion, with a yearly change of -4.77%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €2.07 Billion | -3.93% |
| 2025 | €2.16 Billion | +5.58% |
| 2024 | €2.04 Billion | -28.30% |
| 2023 | €2.85 Billion | -10.54% |
| 2022 | €3.19 Billion | -15.99% |
| 2021 | €3.79 Billion | -38.84% |
| 2020 | €6.20 Billion | -56.85% |
| 2019 | €14.37 Billion | +131.50% |
| 2018 | €6.21 Billion | +2.00% |
| 2017 | €6.08 Billion | +29.60% |
| 2016 | €4.69 Billion | +7.36% |
| 2015 | €4.37 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Galapagos N.V. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.55 Billion USD |
| MoneyControl | $1.55 Billion USD |
| MarketWatch | $1.55 Billion USD |
| marketcap.company | $1.55 Billion USD |
| Reuters | $1.55 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Galapagos N.V.
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory no… Read more